PTCH1-related nevoid basal cell carcinoma syndrome (basal cell nevus syndrome 1) is an autosomal dominant hereditary cancer predisposition syndrome caused by germline pathogenic variants in PTCH1. The primary molecular defect is loss of PTCH1-mediated suppression of smoothened signaling, leading to increased Hedgehog pathway output and GLI-dependent proliferative signaling in susceptible tissues. Clinically, this form is typically associated with high basal cell carcinoma burden, frequent odontogenic keratocysts, and lower medulloblastoma risk than SUFU-related disease.
Ask a research question about PTCH1-related nevoid basal cell carcinoma syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: PTCH1-related nevoid basal cell carcinoma syndrome
creation_date: '2026-03-04T09:02:38Z'
updated_date: '2026-04-22T20:13:21Z'
description: >-
PTCH1-related nevoid basal cell carcinoma syndrome (basal cell nevus syndrome 1)
is an autosomal dominant hereditary cancer predisposition syndrome caused by
germline pathogenic variants in PTCH1. The primary molecular defect is loss of
PTCH1-mediated suppression of smoothened signaling, leading to increased
Hedgehog pathway output and GLI-dependent proliferative signaling in susceptible
tissues. Clinically, this form is typically associated with high basal cell
carcinoma burden, frequent odontogenic keratocysts, and lower medulloblastoma
risk than SUFU-related disease.
category: Mendelian
parents:
- nevoid basal cell carcinoma syndrome
- hereditary cancer predisposition syndrome
- Hedgehog pathway disease
disease_term:
preferred_term: basal cell nevus syndrome 1
term:
id: MONDO:0958174
label: basal cell nevus syndrome 1
synonyms:
- PTCH1-related Gorlin syndrome
- Basal cell nevus syndrome 1
inheritance:
- name: Autosomal Dominant
description: >-
PTCH1-related basal cell nevus syndrome 1 is inherited as an autosomal
dominant disorder with high penetrance and variable expressivity.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "NBCCS is caused by mutations in the PTCH1 gene and is transmitted as an autosomal dominant trait with complete penetrance and variable expressivity."
explanation: Supports autosomal dominant inheritance for PTCH1-driven Gorlin syndrome.
prevalence:
- population: General nevoid basal cell carcinoma syndrome populations
percentage: 1 in 100,000
notes: >-
This syndrome-level prevalence estimate is used for PTCH1-related disease
because PTCH1 is the major molecular cause of NBCCS.
evidence:
- reference: PMID:27054559
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The estimated prevalence is around 1:100,000."
explanation: This cohort overview gives a commonly cited prevalence estimate for nevoid basal cell carcinoma syndrome.
- reference: PMID:30754660
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple basal cell carcinomas (BCC), mainly caused by PTCH1 gene mutations."
explanation: This paper supports applying the syndrome-level prevalence estimate primarily to PTCH1-related NBCCS because PTCH1 is the main causal gene.
pathophysiology:
- name: PTCH1 Loss with SMO Disinhibition
description: >-
PTCH1 normally suppresses SMO in the absence of Hedgehog ligand. Germline
PTCH1 pathogenic variants, followed by somatic second-hit events in target
tissues, remove this restraint and increase smoothened signaling pathway
activity.
genes:
- preferred_term: PTCH1
term:
id: hgnc:9585
label: PTCH1
biological_processes:
- preferred_term: smoothened signaling pathway
modifier: INCREASED
term:
id: GO:0007224
label: smoothened signaling pathway
- preferred_term: negative regulation of smoothened signaling pathway
modifier: DECREASED
term:
id: GO:0045879
label: negative regulation of smoothened signaling pathway
evidence:
- reference: PMID:28596197
reference_title: "First evidence of genotype-phenotype correlations in Gorlin syndrome."
supports: SUPPORT
snippet: "Heterozygous germline variants in PTCH1 and SUFU encoding components of the Sonic hedgehog pathway explain the majority of cases."
explanation: Establishes PTCH1 germline variants as a major upstream mechanism in Gorlin syndrome.
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: PARTIAL
snippet: "NBCCS is caused by mutations in the PTCH1 gene and is transmitted as an autosomal dominant trait with complete penetrance and variable expressivity."
explanation: Supports PTCH1 causality and inherited predisposition biology.
downstream:
- target: GLI-Driven Proliferative Signaling
description: Increased HH pathway output sustains transcriptional programs that promote tumor formation.
evidence:
- reference: PMID:37947611
supports: PARTIAL
snippet: "Approximately, 85% of sporadic BCCs carry mutations in Hedgehog pathway genes, especially in PTCH, SUFU and SMO genes, which lead to the aberrant activation of GLI transcriptional factors, typically silent in cells of adult individuals."
explanation: Supports that PTCH-pathway lesions converge on increased GLI transcriptional output.
- name: SMO-Targetable Dependence
description: >-
Because PTCH1 acts upstream of SMO, many PTCH1-driven lesions remain
sensitive to SMO pathway inhibition, although response durability varies by
secondary genomic context.
evidence:
- reference: PMID:22670904
reference_title: "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome."
supports: SUPPORT
snippet: "Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome."
explanation: Demonstrates direct therapeutic vulnerability of upstream PTCH1-driven disease to SMO inhibition.
- reference: PMID:26169613
supports: PARTIAL
snippet: "Molecular analyses support the hypothesis that SMO inhibitor activity depends on the genomic aberrations within the tumor."
explanation: Indicates that response depends on lesion-level pathway architecture even within HH-driven tumors.
downstream:
- target: Reduced Basal Cell Carcinoma Burden with SMO Inhibition
description: Pharmacologic SMO blockade lowers incident and prevalent BCC burden in many PTCH1-driven patients.
evidence:
- reference: PMID:22670904
reference_title: "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome."
supports: SUPPORT
snippet: "Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome."
explanation: Supports reduced BCC burden downstream of SMO inhibition in PTCH1-driven NBCCS.
phenotypes:
- category: Dermatologic
name: Multiple Basal Cell Carcinomas
frequency: VERY_FREQUENT
diagnostic: true
description: >-
Patients commonly develop multiple BCCs, often beginning in adolescence or
early adulthood, with cumulative burden increasing over time.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "BCCs (varying clinically from flesh-colored papules to ulcerating plaques and in diameter from 1 to 10 mm) are most commonly located on the face, back and chest. The number of BBCs varies from a few to several thousand."
explanation: Documents high and variable BCC burden in PTCH1-driven Gorlin syndrome.
phenotype_term:
preferred_term: Basal cell carcinoma
term:
id: HP:0002671
label: Basal cell carcinoma
- category: Dental
name: Odontogenic Keratocysts of the Jaw
frequency: VERY_FREQUENT
diagnostic: true
description: >-
Jaw keratocysts are a hallmark of PTCH1-related disease and often present in
childhood or adolescence.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "Recurrent jaw cysts occur in 90% of patients."
explanation: Supports high prevalence of odontogenic keratocysts in this genotype.
- reference: PMID:28596197
reference_title: "First evidence of genotype-phenotype correlations in Gorlin syndrome."
supports: PARTIAL
snippet: "Patients with SUFU pathogenic variants were significantly more likely than those with PTCH1 pathogenic variants to develop a medulloblastoma (p=0.009), a meningioma (p=0.02) or an ovarian fibroma (p=0.015), but were less likely to develop a jaw cyst (p=0.0004)."
explanation: Supports relative enrichment of jaw cysts in PTCH1 versus SUFU disease.
phenotype_term:
preferred_term: Odontogenic keratocysts of the jaw
term:
id: HP:0010603
label: Odontogenic keratocysts of the jaw
- category: Oncologic
name: Medulloblastoma
frequency: OCCASIONAL
description: >-
Medulloblastoma risk is increased but lower than in SUFU-related disease.
evidence:
- reference: PMID:25403219
reference_title: "Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations."
supports: SUPPORT
snippet: "We found a < 2% risk in PTCH1 mutation-positive individuals, with a risk up to 20× higher in SUFU mutation-positive individuals."
explanation: Quantifies comparatively lower medulloblastoma risk in PTCH1 carriers.
phenotype_term:
preferred_term: Medulloblastoma
term:
id: HP:0002885
label: Medulloblastoma
- category: Skeletal
name: Abnormal Rib Morphology
frequency: FREQUENT
description: >-
Rib anomalies including bifid ribs are common skeletal findings.
evidence:
- reference: PMID:28596197
reference_title: "First evidence of genotype-phenotype correlations in Gorlin syndrome."
supports: PARTIAL
snippet: "Patients with variants were more likely to be diagnosed earlier (p=0.02), have jaw cysts (p=0.002) and have bifid ribs (p=0.003) or any skeletal abnormality (p=0.003) than patients with no identified mutation."
explanation: Supports frequent rib and skeletal anomalies in mutation-positive Gorlin cohorts dominated by PTCH1.
phenotype_term:
preferred_term: Abnormal rib morphology
term:
id: HP:0000772
label: Abnormal rib morphology
genetic:
- name: PTCH1
association: Causative (Primary)
frequency: VERY_FREQUENT
inheritance:
- name: Autosomal Dominant
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "NBCCS is caused by mutations in the PTCH1 gene and is transmitted as an autosomal dominant trait with complete penetrance and variable expressivity."
explanation: Supports autosomal dominant transmission in PTCH1-related disease.
evidence:
- reference: PMID:28596197
reference_title: "First evidence of genotype-phenotype correlations in Gorlin syndrome."
supports: SUPPORT
snippet: "Heterozygous germline variants in PTCH1 and SUFU encoding components of the Sonic hedgehog pathway explain the majority of cases."
explanation: Supports PTCH1 as the principal causal locus in genotype-positive Gorlin syndrome.
notes: >-
PTCH1 is the dominant causal gene in Gorlin syndrome and underlies basal cell
nevus syndrome 1 (MONDO:0958174).
environmental:
- name: Ultraviolet Radiation
description: >-
UV exposure accelerates the appearance and multiplicity of basal cell carcinomas.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: PARTIAL
snippet: "Patients with NBCCS should strictly avoid an excessive sun exposure."
explanation: Supports UV avoidance as a key preventive strategy.
- name: Ionizing Radiation
description: >-
Ionizing radiation can precipitate aggressive BCC development and should be
avoided when alternatives exist.
evidence:
- reference: PMID:6837723
reference_title: "Cultured diploid fibroblasts from patients with the nevoid basal cell carcinoma syndrome are hypersensitive to killing by ionizing radiation."
supports: SUPPORT
snippet: "Clinical follow-up of these patients, treated with radiotherapy, revealed a predisposition to radiogenic basal cell carcinomas with an unusually short latent period of 6 months to 3 years."
explanation: Supports marked radiation-associated BCC susceptibility in Gorlin syndrome.
treatments:
- name: Vismodegib
description: >-
Oral SMO inhibitor that lowers new and existing BCC burden in PTCH1-related
disease, with tolerability constraints during chronic use.
evidence:
- reference: PMID:22670904
reference_title: "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome."
supports: SUPPORT
snippet: "Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome."
explanation: Randomized trial evidence for efficacy in NBCCS-associated BCC prevention and shrinkage.
- reference: PMID:22670904
reference_title: "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome."
supports: PARTIAL
snippet: "The adverse events associated with treatment led to discontinuation in over half of treated patients."
explanation: Documents long-term tolerability limits that affect treatment strategy.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: vismodegib
term:
id: CHEBI:66903
label: vismodegib
- name: Sonidegib
description: >-
Alternative SMO inhibitor for advanced BCC in patients requiring pathway-targeted
therapy.
evidence:
- reference: PMID:37887561
supports: PARTIAL
snippet: "Vismodegib or sonidegib represent promising treatment options."
explanation: Supports sonidegib use as a pathway-targeted option in Gorlin-associated BCC.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: sonidegib
term:
id: CHEBI:90863
label: sonidegib
- name: Surgical Excision
description: >-
Repeated lesion-directed surgery remains central for local disease control.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "Keratocysts are treated by surgical removal. Surgery for BBCs is indicated when the number of lesions is limited; other treatments include laser ablation, photodynamic therapy and topical chemotherapy."
explanation: Supports surgery as a core local-control treatment in NBCCS.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Sunlight Avoidance
description: >-
Strict UV protection reduces new BCC development.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "Patients with NBCCS should strictly avoid an excessive sun exposure."
explanation: Supports UV-avoidance counseling as a preventive management measure.
treatment_term:
preferred_term: sunlight avoidance
term:
id: MAXO:0000055
label: sunlight avoidance
- name: Genetic Counseling
description: >-
Family counseling and cascade testing are recommended because of autosomal
dominant transmission.
evidence:
- reference: PMID:19032739
reference_title: "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)."
supports: SUPPORT
snippet: "Genetic counseling is mandatory."
explanation: Supports routine genetic counseling for affected families.
treatment_term:
preferred_term: genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
diagnosis:
- name: PTCH1-Targeted Surveillance Strategy
description: >-
Surveillance is stratified by causal gene and includes earlier dermatologic
and odontogenic screening in PTCH1 carriers.
evidence:
- reference: PMID:33860896
supports: SUPPORT
snippet: "In order to allow early detection of BCC, dermatologic examination should start at age 10 in PTCH1, and at age 20 in SUFU PV carriers."
explanation: Supports gene-specific dermatologic surveillance timing in PTCH1 carriers.
- reference: PMID:33860896
supports: SUPPORT
snippet: "Odontogenic keratocyst screening, based on odontologic examination, should begin at age 2 with annual orthopantogram beginning around age 8 for PTCH1 PV carriers only."
explanation: Supports PTCH1-specific odontogenic surveillance recommendations.
datasets:
notes: >-
This entry captures the PTCH1-specific molecular route of Gorlin syndrome.
Relative to SUFU-related disease, PTCH1-related disease more commonly shows
high BCC and jaw cyst burden with lower medulloblastoma risk.
references:
- reference: DOI:10.1007/s10689-021-00247-z
title: 'Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG)'
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: 'Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG)'
supporting_text: Gorlin syndrome (MIM 109,400), a cancer predisposition syndrome related to a constitutional pathogenic variation (PV) of a gene in the Sonic Hedgehog pathway (PTCH1 or SUFU), is associated with a broad spectrum of benign and malignant tumors.
evidence:
- reference: DOI:10.1007/s10689-021-00247-z
reference_title: 'Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG)'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Gorlin syndrome (MIM 109,400), a cancer predisposition syndrome related to a constitutional pathogenic variation (PV) of a gene in the Sonic Hedgehog pathway (PTCH1 or SUFU), is associated with a broad spectrum of benign and malignant tumors.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.1016/b978-0-444-62702-5.00008-1
title: Basal cell nevus syndrome or Gorlin syndrome
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Basal cell nevus syndrome or Gorlin syndrome
supporting_text: Basal cell nevus syndrome or Gorlin syndrome
- reference: DOI:10.1016/j.pathophys.2017.12.004
title: 'Basal cell nevus syndrome (Gorlin syndrome): genetic insights, diagnostic challenges, and unmet milestones'
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: 'Basal cell nevus syndrome (Gorlin syndrome): genetic insights, diagnostic challenges, and unmet milestones'
supporting_text: 'Basal cell nevus syndrome (Gorlin syndrome): genetic insights, diagnostic challenges, and unmet milestones'
- reference: DOI:10.1093/neuonc/nox228
title: 'Germline <i>SUFU</i> mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis'
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Germline mutations of suppressor of fused homolog (SUFU) predispose to sonic hedgehog (SHH) medulloblastoma.
supporting_text: Germline mutations of suppressor of fused homolog (SUFU) predispose to sonic hedgehog (SHH) medulloblastoma.
evidence:
- reference: DOI:10.1093/neuonc/nox228
reference_title: 'Germline <i>SUFU</i> mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Germline mutations of suppressor of fused homolog (SUFU) predispose to sonic hedgehog (SHH) medulloblastoma.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.1111/bjd.15835
title: Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome
supporting_text: Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome
- reference: DOI:10.1158/1078-0432.ccr-17-0595
title: Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Gorlin syndrome and rhabdoid tumor predisposition syndrome (RTPS) are autosomal dominant syndromes associated with an increased risk of childhood-onset brain tumors.
supporting_text: Gorlin syndrome and rhabdoid tumor predisposition syndrome (RTPS) are autosomal dominant syndromes associated with an increased risk of childhood-onset brain tumors.
evidence:
- reference: DOI:10.1158/1078-0432.ccr-17-0595
reference_title: Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome
supports: SUPPORT
evidence_source: OTHER
snippet: Gorlin syndrome and rhabdoid tumor predisposition syndrome (RTPS) are autosomal dominant syndromes associated with an increased risk of childhood-onset brain tumors.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.1158/1078-0432.ccr-23-4033
title: Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Tumors of the central nervous system (CNS) comprise the second most common group of neoplasms in childhood.
supporting_text: Tumors of the central nervous system (CNS) comprise the second most common group of neoplasms in childhood.
evidence:
- reference: DOI:10.1158/1078-0432.ccr-23-4033
reference_title: Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Tumors of the central nervous system (CNS) comprise the second most common group of neoplasms in childhood.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.1159/000535407
title: Further Expanding the Mutational Spectrum of Gorlin Syndrome in Three Unrelated Families
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Gorlin syndrome is a rare, autosomal dominant multi-systemic disorder with a predisposition to the development of cancers such as medulloblastoma and nevoid basal cell carcinoma.
supporting_text: Gorlin syndrome is a rare, autosomal dominant multi-systemic disorder with a predisposition to the development of cancers such as medulloblastoma and nevoid basal cell carcinoma.
evidence:
- reference: DOI:10.1159/000535407
reference_title: Further Expanding the Mutational Spectrum of Gorlin Syndrome in Three Unrelated Families
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Gorlin syndrome is a rare, autosomal dominant multi-systemic disorder with a predisposition to the development of cancers such as medulloblastoma and nevoid basal cell carcinoma.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.1186/s13023-019-1190-6
title: Ocular manifestations in Gorlin-Goltz syndrome
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare genetic disorder that is transmitted in an autosomal dominant manner with complete penetrance and variable expressivity.
supporting_text: Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare genetic disorder that is transmitted in an autosomal dominant manner with complete penetrance and variable expressivity.
evidence:
- reference: DOI:10.1186/s13023-019-1190-6
reference_title: Ocular manifestations in Gorlin-Goltz syndrome
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare genetic disorder that is transmitted in an autosomal dominant manner with complete penetrance and variable expressivity.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.3390/biomedicines12020330
title: Detection of PTCH1 Copy-Number Variants in Mosaic Basal Cell Nevus Syndrome
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Basal cell nevus syndrome (BCNS) is an inherited disorder characterized mainly by the development of basal cell carcinomas (BCCs) at an early age.
supporting_text: Basal cell nevus syndrome (BCNS) is an inherited disorder characterized mainly by the development of basal cell carcinomas (BCCs) at an early age.
evidence:
- reference: DOI:10.3390/biomedicines12020330
reference_title: Detection of PTCH1 Copy-Number Variants in Mosaic Basal Cell Nevus Syndrome
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Basal cell nevus syndrome (BCNS) is an inherited disorder characterized mainly by the development of basal cell carcinomas (BCCs) at an early age.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.3390/cancers13153870
title: Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Basal cell carcinoma (BCC) is a significant public health concern, with more than 3 million cases occurring each year in the United States, and with an increasing incidence.
supporting_text: Basal cell carcinoma (BCC) is a significant public health concern, with more than 3 million cases occurring each year in the United States, and with an increasing incidence.
evidence:
- reference: DOI:10.3390/cancers13153870
reference_title: Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Basal cell carcinoma (BCC) is a significant public health concern, with more than 3 million cases occurring each year in the United States, and with an increasing incidence.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.3390/cancers16122166
title: 'Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study'
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome (GS), is a genetic disorder characterized by the development of multiple cutaneous BCCs due to mutations in the hedgehog signaling pathway.
supporting_text: Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome (GS), is a genetic disorder characterized by the development of multiple cutaneous BCCs due to mutations in the hedgehog signaling pathway.
evidence:
- reference: DOI:10.3390/cancers16122166
reference_title: 'Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome (GS), is a genetic disorder characterized by the development of multiple cutaneous BCCs due to mutations in the hedgehog signaling pathway.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.3390/curroncol30100661
title: 'Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series'
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Nevoid basal-cell carcinoma syndrome (Gorlin syndrome) is characterized by numerous cutaneous basal cell carcinomas mediated by mutations in the hedgehog pathway.
supporting_text: Nevoid basal-cell carcinoma syndrome (Gorlin syndrome) is characterized by numerous cutaneous basal cell carcinomas mediated by mutations in the hedgehog pathway.
evidence:
- reference: DOI:10.3390/curroncol30100661
reference_title: 'Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Nevoid basal-cell carcinoma syndrome (Gorlin syndrome) is characterized by numerous cutaneous basal cell carcinomas mediated by mutations in the hedgehog pathway.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
- reference: DOI:10.3390/ijms21207559
title: 'Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research'
found_in:
- PTCH1-related_Nevoid_Basal_Cell_Carcinoma_Syndrome-deep-research-falcon.md
findings:
- statement: Gorlin syndrome is a skeletal disorder caused by a gain of function mutation in Hedgehog (Hh) signaling.
supporting_text: Gorlin syndrome is a skeletal disorder caused by a gain of function mutation in Hedgehog (Hh) signaling.
evidence:
- reference: DOI:10.3390/ijms21207559
reference_title: 'Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Gorlin syndrome is a skeletal disorder caused by a gain of function mutation in Hedgehog (Hh) signaling.
explanation: Deep research cited this publication as relevant literature for PTCH1-related Nevoid Basal Cell Carcinoma Syndrome.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on PTCH1-related nevoid basal cell carcinoma syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
PTCH1-related nevoid basal cell carcinoma syndrome (NBCCS), commonly called Gorlin syndrome (also Gorlin–Goltz syndrome; basal cell nevus syndrome), is an autosomal-dominant, multisystem cancer-predisposition/developmental disorder characterized by early-onset, often multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, and characteristic skeletal and craniofacial findings, with additional tumor risks (e.g., medulloblastoma, ovarian/cardiac fibromas). (murgia2024gorlinsyndromeassociatedbasal pages 1-2, bresler2016nevoidbasalcell pages 1-3)
Recent summaries continue to emphasize variable expressivity and the importance of multidisciplinary surveillance because individuals may require “dozens or even hundreds of surgical procedures in their lifetime” for BCC management. (murgia2024gorlinsyndromeassociatedbasal pages 1-2)
A concise normalization table is provided below.
| Item | Value | Notes/Source |
|---|---|---|
| Disease name | PTCH1-related nevoid basal cell carcinoma syndrome | Also referred to clinically as Gorlin syndrome / basal cell nevus syndrome; PTCH1 is the major causal gene in most molecularly solved cases (murgia2024gorlinsyndromeassociatedbasal pages 1-2, kolkiran2024furtherexpandingthe pages 1-2, moramarco2019ocularmanifestationsin pages 1-2) |
| MONDO ID | MONDO:0007187 | Open Targets disease association entry for nevoid basal cell carcinoma syndrome mapped this disease to MONDO_0007187 (from tool output in prior evidence summary) (murgia2024gorlinsyndromeassociatedbasal pages 1-2) |
| OMIM (NBCCS) | OMIM:109400 | NBCCS / Gorlin syndrome reported as OMIM #109400 in multiple sources; one 2024 paper listed OMIM #606593, which appears inconsistent with the broader literature and should be interpreted cautiously (kammoun2024theoralfacialmanifestations pages 17-25, alonso2018novelclinicaland pages 1-5, kolkiran2024furtherexpandingthe pages 1-2) |
| Key synonyms | Gorlin syndrome; Gorlin-Goltz syndrome; basal cell nevus syndrome (BCNS); nevoid basal cell carcinoma syndrome (NBCCS); multiple nevoid basal-cell carcinoma syndrome; jaw cyst-basal cell tumor-skeletal anomaly syndrome; fifth phacomatosis | Synonyms compiled from reviews and case literature (murgia2024gorlinsyndromeassociatedbasal pages 1-2, kammoun2024theoralfacialmanifestations pages 17-25, thalakoti2015basalcellnevus pages 1-2) |
| Inheritance | Autosomal dominant | Repeatedly described as autosomal dominant, often with complete or near-complete penetrance and variable expressivity (moramarco2019ocularmanifestationsin pages 1-2, murgia2024gorlinsyndromeassociatedbasal pages 1-2, alonso2018novelclinicaland pages 1-5, thalakoti2015basalcellnevus pages 1-2) |
| Main causal gene (PTCH1) | PTCH1 | PTCH1 loss-of-function is the principal cause; literature states PTCH1 accounts for ~85% to 90% of known-etiology cases and encodes a Sonic Hedgehog pathway receptor/tumor suppressor (moramarco2019ocularmanifestationsin pages 1-2, kolkiran2024furtherexpandingthe pages 1-2) |
| Other genes | SUFU; PTCH2 (contested) | SUFU is an established alternative cause with distinct phenotype/tumor-risk profile; PTCH2 has been reported in some patients but its causal role is questioned/contested in the literature (moramarco2019ocularmanifestationsin pages 1-2, akbari2018basalcellnevus pages 4-4) |
| Prevalence range | Approximately 1 in 31,000 to 1 in 256,000 | Reported ranges vary by cohort/review; commonly cited estimates also include ~1:57,000 and 1:30,827 to 1:164,000 (moramarco2019ocularmanifestationsin pages 1-2, murgia2024gorlinsyndromeassociatedbasal pages 1-2, kolkiran2024furtherexpandingthe pages 1-2, thalakoti2015basalcellnevus pages 1-2) |
| De novo rate | Approximately 20% to 30% | Multiple sources state that about 20–30% of cases arise de novo; familial cases account for the remainder in most series (murgia2024gorlinsyndromeassociatedbasal pages 1-2, moramarco2019ocularmanifestationsin pages 1-2) |
| Penetrance / expressivity | Complete or high penetrance with variable expressivity | Sources consistently describe complete/high penetrance but marked intrafamilial and interfamilial variability in severity and manifestations (moramarco2019ocularmanifestationsin pages 1-2, alonso2018novelclinicaland pages 1-5, thalakoti2015basalcellnevus pages 1-2, bresler2016nevoidbasalcell pages 1-3) |
Table: This table summarizes core identifiers, naming conventions, inheritance, and high-level genetic epidemiology for PTCH1-related nevoid basal cell carcinoma syndrome using only the cited evidence gathered in the session. It is useful as a compact normalization reference for a disease knowledge base entry.
Evidence gaps for identifiers in this run. Orphanet IDs, ICD-10/ICD-11 codes, and MeSH IDs were not present in the retrieved full texts; these should be added from Orphanet/WHO/NLM resources in a follow-on curation step.
Evidence here is aggregated from peer-reviewed cohort/case-series studies, consensus surveillance recommendations, and systematic/ narrative reviews; several sources also include individual case reports (useful for rare manifestations). (murgia2024gorlinsyndromeassociatedbasal pages 1-2, wescott2023sustainedsuppressionof pages 1-2, kolkiran2024furtherexpandingthe pages 1-2)
Primary cause (genetic). PTCH1-related NBCCS is typically caused by heterozygous loss-of-function (tumor suppressor) variants in PTCH1, a core negative regulator of Sonic Hedgehog (SHH) signaling. A 2024 cohort paper states: “heterozygous pathogenic variants in PTCH1 are responsible for 90% of Gorlin syndrome cases,” and that these variants “cause overstimulation of the sonic hedgehog signaling pathway.” (kolkiran2024furtherexpandingthe pages 1-2)
Other genetic causes / locus heterogeneity. SUFU is a well-established alternative cause of Gorlin syndrome with a distinct tumor-risk profile, particularly higher early-childhood medulloblastoma risk. (guerrinirousseau2021currentrecommendationsfor pages 5-6, guerrinirousseau2021currentrecommendationsfor pages 4-5)
PTCH2 uncertainty. Some literature reports PTCH2 variants in NBCCS-like presentations, but at least one genetics-focused study questions whether PTCH2 is truly causal: reporting a healthy individual homozygous for a frameshift variant and concluding that this “question[s] whether variants in PTCH2 are associated with NBCCS.” (kolkiran2024furtherexpandingthe pages 1-2)
Environmental—UV radiation and ionizing radiation. BCC development is strongly modulated by UV exposure and skin type in hedgehog-driven BCC. A molecular genetics review notes that “the molecular basis of BCC involves an interplay of inherited genetic susceptibility and somatic mutations, commonly induced by exposure to UV radiation.” (kilgour2021reviewofthe pages 2-4) Somatic PTCH1 mutations in BCC frequently show UV-signature changes (e.g., ~50% of PTCH1 mutations). (kilgour2021reviewofthe pages 9-12)
Radiation sensitivity and second malignancy risk. Surveillance guidelines emphasize long-term follow-up after radiotherapy due to risk of secondary malignancies in Gorlin syndrome. (guerrinirousseau2021currentrecommendationsfor pages 1-2)
Genotype as a risk stratifier. Tumor risks differ substantially by gene: in PTCH1-related GS, odontogenic keratocysts are frequent and appear largely restricted to PTCH1 disease, whereas SUFU carriers have higher medulloblastoma penetrance and lower BCC/OKC rates. (guerrinirousseau2021currentrecommendationsfor pages 5-6, guerrinirousseau2021currentrecommendationsfor pages 2-4, guerrinirousseau2018germlinesufumutation pages 12-14)
Direct evidence for protective germline variants or specific protective exposures in PTCH1-related NBCCS was not identified in the retrieved corpus. However, consensus guidance recommends sun protection and avoidance of unnecessary ionizing radiation, implying these are modifiable protective behaviors against BCC burden. (hansford2024updateoncancer pages 2-3)
A standard model is germline PTCH1 loss-of-function + somatic second hit, often attributable to UV exposure, yielding constitutive Hedgehog activity and BCC tumorigenesis. (kilgour2021reviewofthe pages 2-4, kilgour2021reviewofthe pages 9-12)
Major and minor clinical criteria remain central for diagnosis and for structuring phenotype capture.
A 2024 clinical series reiterates a combinatorial diagnostic rule: “When a patient meets two major diagnostic criteria and one minor diagnostic criteria, or one major diagnostic criteria and three minor diagnostic criteria, a diagnosis of GS is established.” (murgia2024gorlinsyndromeassociatedbasal pages 1-2)
A 2024 genetics paper lists major criteria including early-onset/multiple BCCs, odontogenic keratocysts before age 20, palmar-plantar pits, lamellar falx cerebri calcification, desmoplastic medulloblastoma, and a first-degree affected relative; it also enumerates minor criteria including rib anomalies, macrocephaly, cleft lip/palate, ovarian/cardiac fibromas, lymphomesenteric cysts, and ocular anomalies (e.g., strabismus/hypertelorism/congenital cataracts/coloboma). (kolkiran2024furtherexpandingthe pages 1-2)
Below are common features with typical onset patterns and frequencies when available.
1) Basal cell carcinomas (BCCs) (clinical sign/tumor) - Typical onset: often adolescence/young adulthood; can occur earlier. (bresler2016nevoidbasalcell pages 1-3, moramarco2019ocularmanifestationsin pages 1-2) - Burden/progression: can be numerous; one review notes BCCs “may number up to 500 in a lifetime.” (bresler2016nevoidbasalcell pages 1-3) - Suggested HPO: Basal cell carcinoma (HP:0002671).
2) Odontogenic keratocysts (OKCs) / keratocystic odontogenic tumors (clinical sign) - Often present in childhood/second decade; a surveillance guideline notes OKCs “have been described in 75–89% of patients” and appear “restricted to PTCH1 associated GS.” (guerrinirousseau2021currentrecommendationsfor pages 2-4) - Suggested HPO: Odontogenic keratocyst (HP:0000684); Jaw cyst (HP:0000673).
3) Falx cerebri calcification (imaging sign) - A 2024 cohort reports: “By the age of 20, over 90% of individuals develop ectopic calcification of the falx cerebri.” (murgia2024gorlinsyndromeassociatedbasal pages 1-2) - Suggested HPO: Calcification of the falx cerebri (HP:0005462).
4) Palmoplantar pits (cutaneous sign) - Often develop in the second decade; described as “2–3 mm in diameter” and “1–3 mm in depth.” (murgia2024gorlinsyndromeassociatedbasal pages 1-2) - Suggested HPO: Palmoplantar pits (HP:0000977).
5) Macrocephaly / craniofacial anomalies (physical manifestation) - A 2024 clinical series indicates ~60% have macrocephaly/frontal bossing/facial dysmorphism. (murgia2024gorlinsyndromeassociatedbasal pages 1-2) - Suggested HPO: Macrocephaly (HP:0000256); Frontal bossing (HP:0002007); Cleft palate (HP:0000175).
6) Skeletal anomalies (e.g., bifid ribs, vertebral anomalies) (imaging/physical) - Included among diagnostic criteria; commonly reported in cohorts. (kolkiran2024furtherexpandingthe pages 1-2, bresler2016nevoidbasalcell pages 1-3) - Suggested HPO: Bifid rib (HP:0000892); Vertebral segmentation defect (HP:0003420).
7) Medulloblastoma risk (tumor) - Particularly associated with SUFU-related disease; a surveillance review reports “approximately 5%” develop medulloblastoma, with mean onset ~2 years and 97% by age 5, and recommends early-life MRI in SUFU carriers. (salvador2017cancersurveillancein pages 1-2) - Suggested HPO: Medulloblastoma (HP:0002885).
8) Ovarian fibroma/fibrothecoma (tumor) - Included in minor criteria; cohort data show ovarian fibromas detected by pelvic ultrasound and can be clinically subtle. (guerrinirousseau2021currentrecommendationsfor pages 2-4) - Suggested HPO: Ovarian fibroma (HP:0000131).
9) Ocular manifestations (clinical signs) - An Orphanet Journal of Rare Diseases cohort quantifies multiple ocular findings: hypertelorism 45.5%, congenital cataract 18%, nystagmus 9%, colobomas 9%; additionally, the study “highlights strabismus (63% of the patients), epiretinal membranes (36%) and myelinated optic nerve fiber layers (36%) as the most frequent ophthalmological findings.” (moramarco2019ocularmanifestationsin pages 1-2) - Suggested HPO: Strabismus (HP:0000486); Hypertelorism (HP:0000316); Congenital cataract (HP:0000519); Coloboma (HP:0000589).
Direct QoL instrument data (e.g., SF-36/EQ-5D) were not available in the retrieved texts. However, treatment series emphasize a large lifelong surgical burden and disfigurement risk from repeated BCC excisions, supporting high QoL impact. (murgia2024gorlinsyndromeassociatedbasal pages 1-2)
Variant classes. In a 22-patient Spanish cohort, PTCH1 sequencing identified numerous truncating variants; the authors report “Most of them produce a truncated protein which is unable to supress Smoothened protein and continuously activates the downstream pathway,” and that “Most of the mutations found were frameshift (52.2%).” (alonso2018novelclinicaland pages 1-5, alonso2018novelclinicaland pages 5-9)
CNVs and mosaicism (recent development, 2024). A 2024 methods paper highlights postzygotic mosaic PTCH1 CNVs and the need for sensitive quantification. It reports ddPCR detected a PTCH1 CNV duplication and quantified mosaicism that MLPA missed in blood, supporting ddPCR as an adjunct for low-grade mosaic cases and recurrence-risk counseling. (roemen2024detectionofptch1 pages 5-7)
De novo rate. Multiple sources estimate de novo variants account for ~20–30% of cases. (moramarco2019ocularmanifestationsin pages 1-2)
PTCH1 pathogenic germline variants act as loss-of-function in a tumor suppressor pathway; tumorigenesis is consistent with Knudson’s two-hit model, where somatic inactivation of the remaining allele in target tissues leads to clonal expansion and tumor formation. (bresler2016nevoidbasalcell pages 1-3, kilgour2021reviewofthe pages 2-4)
Clinical series suggest modifier genes and environment contribute to variable expressivity; one 2024 paper explicitly notes expressivity “may be attributed to modifier genes (SUFU and PTCH2) and environmental exposure.” (murgia2024gorlinsyndromeassociatedbasal pages 1-2)
Direct NBCCS-specific methylation/histone datasets were not retrieved here. Related oncologic research shows that Hedgehog pathway transcriptional output can be epigenetically regulated through BET bromodomain proteins (e.g., BRD4 occupancy at GLI promoters), which has therapeutic implications in Hedgehog-driven tumors including BCC and medulloblastoma. ()
Core concept. PTCH1 normally suppresses SMO activity. A pathology review states: “PTCH1… maintains smoothened (SMO) in its inactive/unphosphorylated state,” and PTCH1 loss leads to constitutive Hedgehog pathway activation with GLI transcription factor activity. (bresler2016nevoidbasalcell pages 1-3)
Causal chain (simplified). 1) Germline PTCH1 loss-of-function → reduced repression of SMO. (bresler2016nevoidbasalcell pages 1-3, alonso2018novelclinicaland pages 1-5) 2) SMO activation → GLI transcriptional activation (e.g., GLI1) → increased expression of genes involved in proliferation/survival/angiogenesis and altered differentiation. (kilgour2021reviewofthe pages 2-4, kammoun2024theoralfacialmanifestations pages 34-38) 3) Somatic second hit (often UV-driven) in target tissue → biallelic PTCH1 inactivation → clonal expansion → BCC/OKC and other neoplasms. (kilgour2021reviewofthe pages 2-4, kilgour2021reviewofthe pages 9-12)
UV mechanism integration. A molecular genetics review reports that somatic PTCH1 mutations occur in up to ~75% of BCCs and that overall HH-pathway alterations occur in ~90% of tumors; importantly, ~50% of PTCH1 mutations have UV-signature changes, aligning UV with the “second hit” mechanism. (kilgour2021reviewofthe pages 9-12)
Primary organs/tissues - Skin (cutaneous BCCs; palmar/plantar pits). (bresler2016nevoidbasalcell pages 1-3, murgia2024gorlinsyndromeassociatedbasal pages 1-2) - Jaw/maxillofacial tissues (odontogenic keratocysts). (guerrinirousseau2021currentrecommendationsfor pages 2-4) - Cranial meninges/brain (falx calcification; medulloblastoma risk in subsets; meningioma risk particularly in SUFU carriers). (guerrinirousseau2021currentrecommendationsfor pages 5-6, guerrinirousseau2021currentrecommendationsfor pages 4-5) - Gonads (ovarian fibromas/fibrothecomas). (guerrinirousseau2021currentrecommendationsfor pages 5-6, hansford2024updateoncancer pages 2-3)
UBERON suggestions - Skin of body (UBERON:0002097) - Mandible (UBERON:0001684); Maxilla (UBERON:0000166) - Cerebellum (UBERON:0002037) - Ovary (UBERON:0000992)
Autosomal dominant inheritance with high/complete penetrance and variable expressivity is repeatedly reported in the clinical literature. (moramarco2019ocularmanifestationsin pages 1-2, thalakoti2015basalcellnevus pages 1-2)
Prevalence estimates vary by population and ascertainment. A 2024 clinical study notes a commonly cited prevalence of 1:57,000 and a theoretical range of 1:30,827 to 1:164,000. (murgia2024gorlinsyndromeassociatedbasal pages 1-2) Other literature quotes ranges up to 1 in 256,000. (moramarco2019ocularmanifestationsin pages 1-2, kolkiran2024furtherexpandingthe pages 1-2)
A 2024 review/series reports “About 20–30% of GS cases are caused by a de novo pathogenetic variation, whereas 70–80% of cases have a relevant family history.” (murgia2024gorlinsyndromeassociatedbasal pages 1-2)
Diagnosis may be made using combinations of major/minor criteria; one cohort provides an explicit rule set: diagnosis can be established by “(1) one major criteria and genetic confirmation; or (2) two major criteria; or (3) one major and two minor criteria.” (kolkiran2024furtherexpandingthe pages 1-2)
Given locus heterogeneity and CNVs/mosaicism, evidence supports: - PTCH1 sequencing plus CNV detection (e.g., MLPA), and consideration of more sensitive quantitative methods (ddPCR) when mosaicism is suspected. (roemen2024detectionofptch1 pages 5-7) - If PTCH1 is negative in a clinically compatible case, consider SUFU (and cautiously PTCH2) testing. (akbari2018basalcellnevus pages 4-4)
Mortality is typically driven by malignancies (rare metastatic BCC; medulloblastoma/other tumors) rather than the developmental features themselves. Treatment series emphasize long-term morbidity from high BCC burden and repeated procedures. (murgia2024gorlinsyndromeassociatedbasal pages 1-2, wescott2023sustainedsuppressionof pages 1-2)
For SUFU-associated medulloblastoma, a Neuro-Oncology cohort reports 5-year DFS/OS of 37.5%/67.0% in their series and notes additional second malignancies, reinforcing the need for dedicated surveillance and treatment planning. (guerrinirousseau2018germlinesufumutation pages 12-14)
Cutaneous BCC management remains anchored in lesion-directed dermatologic therapies (surgery, destructive modalities), but systemic hedgehog pathway inhibitors (HHIs) have become critical for high-burden disease.
Real-world effectiveness (2023 case series). In 10 Gorlin patients treated with HHIs, “All patients achieved a complete remission,” and treatment reduced new BCCs from “28.3 ± 24.6 prior to treatment” to “1.4 ± 2.0 during treatment (p = 0.0048)” with a median time to new BCC of 47.3 months. (wescott2023sustainedsuppressionof pages 1-2)
Comparative effectiveness/safety (2024 retrospective cohort). In a 16-patient cohort, sonidegib had higher 4-month clinical remission (61.5%) than vismodegib (16.7%), and fewer patients had side effects (57.9% vs 100%). (murgia2024gorlinsyndromeassociatedbasal pages 5-7)
Adverse events. Common class adverse effects include dysgeusia, fatigue, alopecia, muscle spasms, and weight loss. (murgia2024gorlinsyndromeassociatedbasal pages 2-4)
Implementation detail: schedule modification. Both 2023 and 2024 series report dose/schedule adjustments (interruptions/holidays) to improve tolerability without obvious loss of efficacy, enabling longer-term treatment. (wescott2023sustainedsuppressionof pages 9-10, murgia2024gorlinsyndromeassociatedbasal pages 1-2)
ClinicalTrials.gov records include multiple trials of topical patidegib gel in Gorlin syndrome, including a completed phase 3 trial (NCT03703310) and an active phase 3 trial (NCT06050122). (hansford2024updateoncancer media d17aac4b)
Consensus pediatric cancer predisposition guidance includes behavioral and exposure avoidance: individuals “should be counseled on sun protection and avoidance of ionizing irradiation unless absolutely necessary.” (hansford2024updateoncancer pages 2-3)
Natural disease analogs in companion animals were not identified in the retrieved sources for this run.
Mouse models. Ptch1-deficient mice are central NBCCS models. A 2020 review summarizes that Ptch1 mutant mouse lines are “prone to tumor development and skeletal abnormalities and exhibited increased susceptibility to irradiation.” (onodera2020gorlinsyndromerecent pages 6-8)
iPSC and cellular models. Patient-derived iPSCs and stromal cell models capture pathway and differentiation phenotypes; for example, reduced conversion of full-length Gli3 to its repressor form was observed in Ptch1+/− mice and GS iPS cells, linking Hedgehog dysregulation to osteogenic programs. (onodera2020gorlinsyndromerecent pages 6-8)
Cross-species developmental genetics. Drosophila patched/hedgehog mutants and mammalian GLI1 transfection models provide mechanistic evidence connecting HH/GLI activation to proliferative phenotypes relevant to tumorigenesis. (kammoun2024theoralfacialmanifestations pages 34-38)
1) Genotype-stratified surveillance is implemented in expert recommendations and summarized in 2024 guidance (skin exams, dental imaging for PTCH1; intensive early-life brain MRI for SUFU). (hansford2024updateoncancer pages 2-3, hansford2024updateoncancer media d17aac4b)
2) Long-term systemic HHI therapy (vismodegib/sonidegib) is used to reduce surgical burden and suppress new lesion formation, with real-world cohorts reporting dramatic reductions in incident BCCs and frequent need for tolerability-driven schedule modification. (wescott2023sustainedsuppressionof pages 1-2, murgia2024gorlinsyndromeassociatedbasal pages 5-7)
3) Improved molecular diagnostics for mosaicism/CNVs (ddPCR) are emerging as practical clinical tools to avoid missed diagnoses and better estimate recurrence risk in families. (roemen2024detectionofptch1 pages 5-7)
The following extracted table image summarizes surveillance recommendations stratified by PTCH1 vs SUFU (skin exams, dental orthopantomogram, brain MRI schedules, and pelvic ultrasound). (hansford2024updateoncancer media d17aac4b)
References
(murgia2024gorlinsyndromeassociatedbasal pages 1-2): Giulia Murgia, Luca Valtellini, Nerina Denaro, Gianluca Nazzaro, Paolo Bortoluzzi, Valentina Benzecry, Emanuela Passoni, and Angelo Valerio Marzano. Gorlin syndrome-associated basal cell carcinomas treated with vismodegib or sonidegib: a retrospective study. Cancers, 16:2166, Jun 2024. URL: https://doi.org/10.3390/cancers16122166, doi:10.3390/cancers16122166. This article has 15 citations.
(bresler2016nevoidbasalcell pages 1-3): Scott C. Bresler, Bonnie L. Padwa, and Scott R. Granter. Nevoid basal cell carcinoma syndrome (gorlin syndrome). Head and Neck Pathology, 10:119-124, Mar 2016. URL: https://doi.org/10.1007/s12105-016-0706-9, doi:10.1007/s12105-016-0706-9. This article has 219 citations and is from a peer-reviewed journal.
(kolkiran2024furtherexpandingthe pages 1-2): Abdulkerim Kolkiran, Pelin Özlem Şimşek-Kiper, Göknur Topaloğlu Yasan, Beren Karaosmanoğlu, Ekim Taşkıran, Gülen Eda Utine, Hakan H. Tüz, and Koray Boduroğlu. Further expanding the mutational spectrum of gorlin syndrome in three unrelated families. Molecular Syndromology, 15:175-184, Jan 2024. URL: https://doi.org/10.1159/000535407, doi:10.1159/000535407. This article has 3 citations and is from a peer-reviewed journal.
(moramarco2019ocularmanifestationsin pages 1-2): Antonietta Moramarco, Ehud Himmelblau, Emanuele Miraglia, Fabiana Mallone, Vincenzo Roberti, Federica Franzone, Chiara Iacovino, Sandra Giustini, and Alessandro Lambiase. Ocular manifestations in gorlin-goltz syndrome. Orphanet Journal of Rare Diseases, Sep 2019. URL: https://doi.org/10.1186/s13023-019-1190-6, doi:10.1186/s13023-019-1190-6. This article has 43 citations and is from a peer-reviewed journal.
(kammoun2024theoralfacialmanifestations pages 17-25): K Kammoun. The oral-facial manifestations of gorlin syndrome. Unknown journal, 2024.
(alonso2018novelclinicaland pages 1-5): N. Alonso, N. Alonso, Javier Cañueto, S. Círia, Elena Bueno, I. Palacios‐Álvarez, M. Alegre, C. Badenas, A. Barreiro, L. Pena, C. Maldonado, M. Nespeira‐Jato, C. Peña-penabad, A. Azon, M. Gavrilova, I. Ferrer, O. Sanmartín, L. Robles, Á. Hernández-Martín, Miguel Urioste, S. Puig, Lluís Puig, and Rogelio González-Sarmiento. Novel clinical and molecular findings in spanish patients with naevoid basal cell carcinoma syndrome. British Journal of Dermatology, 178:198-206, Jan 2018. URL: https://doi.org/10.1111/bjd.15835, doi:10.1111/bjd.15835. This article has 10 citations and is from a highest quality peer-reviewed journal.
(thalakoti2015basalcellnevus pages 1-2): Srikanth Thalakoti and Thomas Geller. Basal cell nevus syndrome or gorlin syndrome. Handbook of clinical neurology, 132:119-28, Jan 2015. URL: https://doi.org/10.1016/b978-0-444-62702-5.00008-1, doi:10.1016/b978-0-444-62702-5.00008-1. This article has 49 citations.
(akbari2018basalcellnevus pages 4-4): Maryam Akbari, Harold Chen, Grace Guo, Zachary Legan, and Ghali Ghali. Basal cell nevus syndrome (gorlin syndrome): genetic insights, diagnostic challenges, and unmet milestones. Pathophysiology : the official journal of the International Society for Pathophysiology, 25 2:77-82, Jun 2018. URL: https://doi.org/10.1016/j.pathophys.2017.12.004, doi:10.1016/j.pathophys.2017.12.004. This article has 53 citations.
(wescott2023sustainedsuppressionof pages 1-2): Raquel Wescott and Wolfram Samlowski. Sustained suppression of gorlin syndrome-associated basal cell carcinomas with vismodegib or sonidegib: a case series. Current Oncology, 30:9156-9167, Oct 2023. URL: https://doi.org/10.3390/curroncol30100661, doi:10.3390/curroncol30100661. This article has 7 citations.
(guerrinirousseau2021currentrecommendationsfor pages 5-6): L. Guerrini-Rousseau, M. J. Smith, C. P. Kratz, B. Doergeloh, S. Hirsch, S. M. J. Hopman, M. Jorgensen, M. Kuhlen, O. Michaeli, T. Milde, V. Ridola, A. Russo, H. Salvador, N. Waespe, B. Claret, L. Brugieres, and D. G. Evans. Current recommendations for cancer surveillance in gorlin syndrome: a report from the siope host genome working group (siope hgwg). Familial Cancer, 20:317-325, Apr 2021. URL: https://doi.org/10.1007/s10689-021-00247-z, doi:10.1007/s10689-021-00247-z. This article has 51 citations and is from a peer-reviewed journal.
(guerrinirousseau2021currentrecommendationsfor pages 4-5): L. Guerrini-Rousseau, M. J. Smith, C. P. Kratz, B. Doergeloh, S. Hirsch, S. M. J. Hopman, M. Jorgensen, M. Kuhlen, O. Michaeli, T. Milde, V. Ridola, A. Russo, H. Salvador, N. Waespe, B. Claret, L. Brugieres, and D. G. Evans. Current recommendations for cancer surveillance in gorlin syndrome: a report from the siope host genome working group (siope hgwg). Familial Cancer, 20:317-325, Apr 2021. URL: https://doi.org/10.1007/s10689-021-00247-z, doi:10.1007/s10689-021-00247-z. This article has 51 citations and is from a peer-reviewed journal.
(kilgour2021reviewofthe pages 2-4): James M. Kilgour, Justin L. Jia, and Kavita Y. Sarin. Review of the molecular genetics of basal cell carcinoma; inherited susceptibility, somatic mutations, and targeted therapeutics. Cancers, 13:3870, Jul 2021. URL: https://doi.org/10.3390/cancers13153870, doi:10.3390/cancers13153870. This article has 43 citations.
(kilgour2021reviewofthe pages 9-12): James M. Kilgour, Justin L. Jia, and Kavita Y. Sarin. Review of the molecular genetics of basal cell carcinoma; inherited susceptibility, somatic mutations, and targeted therapeutics. Cancers, 13:3870, Jul 2021. URL: https://doi.org/10.3390/cancers13153870, doi:10.3390/cancers13153870. This article has 43 citations.
(guerrinirousseau2021currentrecommendationsfor pages 1-2): L. Guerrini-Rousseau, M. J. Smith, C. P. Kratz, B. Doergeloh, S. Hirsch, S. M. J. Hopman, M. Jorgensen, M. Kuhlen, O. Michaeli, T. Milde, V. Ridola, A. Russo, H. Salvador, N. Waespe, B. Claret, L. Brugieres, and D. G. Evans. Current recommendations for cancer surveillance in gorlin syndrome: a report from the siope host genome working group (siope hgwg). Familial Cancer, 20:317-325, Apr 2021. URL: https://doi.org/10.1007/s10689-021-00247-z, doi:10.1007/s10689-021-00247-z. This article has 51 citations and is from a peer-reviewed journal.
(guerrinirousseau2021currentrecommendationsfor pages 2-4): L. Guerrini-Rousseau, M. J. Smith, C. P. Kratz, B. Doergeloh, S. Hirsch, S. M. J. Hopman, M. Jorgensen, M. Kuhlen, O. Michaeli, T. Milde, V. Ridola, A. Russo, H. Salvador, N. Waespe, B. Claret, L. Brugieres, and D. G. Evans. Current recommendations for cancer surveillance in gorlin syndrome: a report from the siope host genome working group (siope hgwg). Familial Cancer, 20:317-325, Apr 2021. URL: https://doi.org/10.1007/s10689-021-00247-z, doi:10.1007/s10689-021-00247-z. This article has 51 citations and is from a peer-reviewed journal.
(guerrinirousseau2018germlinesufumutation pages 12-14): Léa Guerrini-Rousseau, Christelle Dufour, Pascale Varlet, Julien Masliah-Planchon, Franck Bourdeaut, Marine Guillaud-Bataille, Rachid Abbas, Anne-Isabelle Bertozzi, Fanny Fouyssac, Sophie Huybrechts, Stéphanie Puget, Brigitte Bressac-De Paillerets, Olivier Caron, Nicolas Sevenet, Marina Dimaria, Sophie Villebasse, Olivier Delattre, Dominique Valteau-Couanet, Jacques Grill, and Laurence Brugières. Germline sufu mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro-Oncology, 20:1122–1132, Jul 2018. URL: https://doi.org/10.1093/neuonc/nox228, doi:10.1093/neuonc/nox228. This article has 85 citations and is from a domain leading peer-reviewed journal.
(hansford2024updateoncancer pages 2-3): Jordan R. Hansford, Anirban Das, Rose B. McGee, Yoshiko Nakano, Jack Brzezinski, Sarah R. Scollon, Surya P. Rednam, Jaclyn Schienda, Orli Michaeli, Sun Young Kim, Mary-Louise C. Greer, Rosanna Weksberg, Douglas R. Stewart, William D. Foulkes, Uri Tabori, Kristian W. Pajtler, Stefan M. Pfister, Garrett M. Brodeur, and Junne Kamihara. Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2342-2350, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-4033, doi:10.1158/1078-0432.ccr-23-4033. This article has 49 citations.
(salvador2017cancersurveillancein pages 1-2): H. Salvador, Vivian Y. Chang, A. Erez, S. Voss, H. Scott, S. Plon, H. Druker, W. Foulkes, J. Kamihara, D. Evans, Laurence Brugi, G. Brodeur, K. Janeway, W. Kohlmann, K. Nathanson, J. Schiffman, L. Doros, J. Wilmott, H. Rizos, R. Scolyer, L. Marcus, and P. Keegan. Cancer surveillance in gorlin syndrome and rhabdoid tumor predisposition syndrome. Clinical Cancer Research, 23:e62-e67, Jun 2017. URL: https://doi.org/10.1158/1078-0432.ccr-17-0595, doi:10.1158/1078-0432.ccr-17-0595. This article has 223 citations and is from a highest quality peer-reviewed journal.
(alonso2018novelclinicaland pages 5-9): N. Alonso, N. Alonso, Javier Cañueto, S. Círia, Elena Bueno, I. Palacios‐Álvarez, M. Alegre, C. Badenas, A. Barreiro, L. Pena, C. Maldonado, M. Nespeira‐Jato, C. Peña-penabad, A. Azon, M. Gavrilova, I. Ferrer, O. Sanmartín, L. Robles, Á. Hernández-Martín, Miguel Urioste, S. Puig, Lluís Puig, and Rogelio González-Sarmiento. Novel clinical and molecular findings in spanish patients with naevoid basal cell carcinoma syndrome. British Journal of Dermatology, 178:198-206, Jan 2018. URL: https://doi.org/10.1111/bjd.15835, doi:10.1111/bjd.15835. This article has 10 citations and is from a highest quality peer-reviewed journal.
(roemen2024detectionofptch1 pages 5-7): Guido M. J. M. Roemen, Tom E. J. Theunissen, Ward W. J. Hoezen, Anja R. M. Steyls, Aimee D. C. Paulussen, Klara Mosterd, Elisa Rahikkala, Axel zur Hausen, Ernst Jan M. Speel, and Michel van Geel. Detection of ptch1 copy-number variants in mosaic basal cell nevus syndrome. Biomedicines, 12:330, Jan 2024. URL: https://doi.org/10.3390/biomedicines12020330, doi:10.3390/biomedicines12020330. This article has 1 citations.
(kammoun2024theoralfacialmanifestations pages 34-38): K Kammoun. The oral-facial manifestations of gorlin syndrome. Unknown journal, 2024.
(onodera2020gorlinsyndromerecent pages 6-8): Shoko Onodera, Yuriko Nakamura, and Toshifumi Azuma. Gorlin syndrome: recent advances in genetic testing and molecular and cellular biological research. International Journal of Molecular Sciences, 21:7559, Oct 2020. URL: https://doi.org/10.3390/ijms21207559, doi:10.3390/ijms21207559. This article has 84 citations.
(murgia2024gorlinsyndromeassociatedbasal pages 5-7): Giulia Murgia, Luca Valtellini, Nerina Denaro, Gianluca Nazzaro, Paolo Bortoluzzi, Valentina Benzecry, Emanuela Passoni, and Angelo Valerio Marzano. Gorlin syndrome-associated basal cell carcinomas treated with vismodegib or sonidegib: a retrospective study. Cancers, 16:2166, Jun 2024. URL: https://doi.org/10.3390/cancers16122166, doi:10.3390/cancers16122166. This article has 15 citations.
(murgia2024gorlinsyndromeassociatedbasal pages 2-4): Giulia Murgia, Luca Valtellini, Nerina Denaro, Gianluca Nazzaro, Paolo Bortoluzzi, Valentina Benzecry, Emanuela Passoni, and Angelo Valerio Marzano. Gorlin syndrome-associated basal cell carcinomas treated with vismodegib or sonidegib: a retrospective study. Cancers, 16:2166, Jun 2024. URL: https://doi.org/10.3390/cancers16122166, doi:10.3390/cancers16122166. This article has 15 citations.
(wescott2023sustainedsuppressionof pages 9-10): Raquel Wescott and Wolfram Samlowski. Sustained suppression of gorlin syndrome-associated basal cell carcinomas with vismodegib or sonidegib: a case series. Current Oncology, 30:9156-9167, Oct 2023. URL: https://doi.org/10.3390/curroncol30100661, doi:10.3390/curroncol30100661. This article has 7 citations.
(hansford2024updateoncancer media d17aac4b): Jordan R. Hansford, Anirban Das, Rose B. McGee, Yoshiko Nakano, Jack Brzezinski, Sarah R. Scollon, Surya P. Rednam, Jaclyn Schienda, Orli Michaeli, Sun Young Kim, Mary-Louise C. Greer, Rosanna Weksberg, Douglas R. Stewart, William D. Foulkes, Uri Tabori, Kristian W. Pajtler, Stefan M. Pfister, Garrett M. Brodeur, and Junne Kamihara. Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2342-2350, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-4033, doi:10.1158/1078-0432.ccr-23-4033. This article has 49 citations.